Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult
NCT06099613
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Interventions
BIOLOGICAL:
EG-COVII
Sponsor
EyeGene Inc.